

DAFTAR PUSTAKA

- Alghorabi, A. A., Kabel, A. M., Elmaaboud, M. A. A., & Doxorubicin, ". (2019). Insights into Dynamics, Clinical Uses and Adverse Effects. *Journal of Cancer Research and Treatment*, 7(1), 17–20. <https://doi.org/10.12691/jcrt-7-1-3>
- Aprianto, M. M. (2024). Uji Aktivitas Antikanker Mikroalga (*Chlorella pyrenoidosa*) Pada Sel Kanker Payudara *Triple Negative* MDA-MB-231. Skripsi. Universitas Pertahanan Republik Indonesia. Bogor.
- Azam, R., Kothari, R., Singh, H. M., Ahmad, S., Sari, A., & Tyagi, V. V. (2022). Cultivation of two *Chlorella* species in Open sewage contaminated channel wastewater for biomass and biochemical profiles: Comparative lab-scale approach. *Journal of Biotechnology*, 344, 24–31. <https://doi.org/10.1016/j.jbiotec.2021.11.006>
- Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi Kalbolandi, S., Safari, E., & Farahmand, L. (2020). Breast cancer: Biology, biomarkers, and treatments. *International Immunopharmacology*, 84, 106535. <https://doi.org/10.1016/j.intimp.2020.106535>
- Borri, F., & Granaglia, A. (2021). Pathology of triple negative breast cancer. *Seminars in Cancer Biology*, 72, 136–145. <https://doi.org/10.1016/j.semcancer.2020.06.005>
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 74(3), 229–263. <https://doi.org/10.3322/caac.21834>
- Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009). Doxorubicin: The Good, the Bad and the Ugly Effect. *Current Medicinal Chemistry*, 16(25), 3267–3285. <https://doi.org/10.2174/092986709788803312>
- Champenois, J., Marfaing, H., & Pierre, R. (2015). Review of the taxonomic revision of *Chlorella* and consequences for its food uses in Europe. *Journal of Applied Phycology*, 27(5), 1845–1851. <https://doi.org/10.1007/s10811-014-0431-2>
- Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019). Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors

- in Breast Cancer: The Past, the Present and the Future. *Journal of Cancer*, 10(26), 6608–6617. <https://doi.org/10.7150/jca.33079>
- Cheng, Y., Lin, L., Li, X., Lu, A., Hou, C., Wu, Q., Hu, X., Zhou, Z., Chen, Z., & Tang, F. (2021). ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc. *Cancer Cell International*, 21(1), 32. <https://doi.org/10.1186/s12935-020-01727-5>
- Darzynkiewicz, Z., Huang, X., & Zhao, H. (2017). Analysis of Cellular DNA Content by Flow Cytometry. *Current Protocols in Immunology*, 119(1). <https://doi.org/10.1002/cpim.36>
- D'Angelo, N. A., Noronha, M. A., Câmara, M. C. C., Kurnik, I. S., Feng, C., Araujo, V. H. S., Santos, J. H. P. M., Feitosa, V., Molino, J. V.D., Rangel-Yagui, C. O., Chorilli, M., Ho, E. A., & Lopes, A. M. (2022). Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years. *Biomaterials Advances*, 133, 112623. <https://doi.org/10.1016/j.bmsec.2021.112623>
- Eom, J. W., Lim, J. W., & Kim, H. (2023). Lutein Induces Reactive Oxygen Species-Mediated Apoptosis in Gastric Cancer AGS Cells via NADPH Oxidase Activation. *Molecules*, 28(3), 1178. <https://doi.org/10.3390/molecules28031178>
- Fuentes-Antrás, J., Bedard, P. L., & Cescon, D. W. (2024). Seize the engine: Emerging cell cycle targets in breast cancer. *Clinical and Translational Medicine*, 14(1). <https://doi.org/10.1002/ctm2.1544>
- Grada, A., Otero-Vinas, M., Prieto-Castrillo, F., Obagi, Z., & Falanga, V. (2017). Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. *Journal of Investigative Dermatology*, 137(2), e11–e16. <https://doi.org/10.1016/j.jid.2016.11.020>
- Gilmour D. J. (2019). Microalgae for biofuel production. *Advances in applied microbiology*, 109, 1–30. <https://doi.org/10.1016/bs.aambs.2019.10.001>
- Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. *Cancer Discovery*, 12(1), 31–46. <https://doi.org/10.1158/2159-8290.CD-21-1059>
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>

- Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. *Journal of Cancer Research and Practice*, 4(4), 127–129. <https://doi.org/10.1016/j.jcrpr.2017.07.001>
- Huang, Z., Yu, P., & Tang, J. (2020). Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model. *OncoTargets and therapy*, 13, 5395–5405. <https://doi.org/10.2147/OTT.S249756>
- Heimes, A.-S., & Schmidt, M. (2019). Atezolizumab for the treatment of triple-negative breast cancer. *Expert Opinion on Investigational Drugs*, 28(1), 1–5. <https://doi.org/10.1080/13543784.2019.1552255>
- Kamiloglu, S., Sari, G., Ozdal, T., & Capanoglu, E. (2020a). Guidelines for cell viability assays. *Food Frontiers*, 1(3), 332–349. <https://doi.org/10.1002/fft2.44>
- Kamiloglu, S., Sari, G., Ozdal, T., & Capanoglu, E. (2020b). Guidelines for cell viability assays. *Food Frontiers*, 1(3), 332–349. <https://doi.org/10.1002/fft2.44>
- Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kaluzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023). Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. *Cells*, 12(4), 659. <https://doi.org/10.3390/cells12040659>
- Kim, K. H., & Sederstrom, J. M. (2015). Assaying Cell Cycle Status Using Flow Cytometry. *Current Protocols in Molecular Biology*, 111(1). <https://doi.org/10.1002/0471142727.mb2806s111>
- Kubatka, P., Kapinová, A., Kružliak, P., Kello, M., Výbohová, D., Kajo, K., Novák, M., Chripková, M., Adamkov, M., Pěč, M., Mojžiš, J., Bojková, B., Kássayová, M., Stolarová, N., & Dobrota, D. (2015). Antineoplastic effects of *Chlorella pyrenoidosa* in the breast cancer model. *Nutrition*, 31(4), 560–569. <https://doi.org/10.1016/j.nut.2014.08.010>
- Kemenkes RI. (2018). Pedoman Nasional Pelayanan Kedokteran Tatalaksana Kanker Payudara. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018.
- Kyadari, M., Fatma, T., Azad, R., & Velpandian, T. (2013). Evaluation of antiangiogenic and antiproliferative potential of the organic extract of green algae *Chlorella pyrenoidosa*. *Indian Journal of Pharmacology*, 45(6), 569. <https://doi.org/10.4103/0253-7613.121366>
- Lemieszek, M. K., & Rzeski, W. (2023b). Synergism of antiproliferative effects of young green barley and *Chlorella* water extracts against human breast cancer cells. *Annals of Agricultural and Environmental*

Medicine: AAEM, 30(2), 273–280.
<https://doi.org/10.26444/aaem/166267>

- Lewandowska, A., Rudzki, M., Rudzki, S., Lewandowski, T., & Laskowska, B. (2019). Environmental risk factors for cancer – review paper. *Annals of Agricultural and Environmental Medicine*, 26(1), 1–7. <https://doi.org/10.26444/aaem/94299>
- Lin, P.-Y., Tsai, C.-T., Chuang, W.-L., Chao, Y.-H., Pan, I.-H., Chen, Y.-K., Lin, C.-C., & Wang, B.-Y. (2017). *Chlorella sorokiniana* induces mitochondrial-mediated apoptosis in human non-small cell lung cancer cells and inhibits xenograft tumor growth in vivo. *BMC Complementary and Alternative Medicine*, 17(1), 88. <https://doi.org/10.1186/s12906-017-1611-9>
- Liu, H. C., Chiang, C. C., Lin, C. H., Chen, C. S., Wei, C. W., Lin, S. Y., Yiang, G. T., & Yu, Y. L. (2020). Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells. *International Journal of Medical Sciences*, 17(8), 1015–1022. <https://doi.org/10.7150/ijms.40131>
- Liu, K., Liu, P. cheng, Liu, R., & Wu, X. (2015). Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. *Medical Science Monitor Basic Research*, 21, 15–20. <https://doi.org/10.12659/MSMBR.893327>
- Makhoul, I., Atiq, M., Alwbari, A., & Kieber-Emmons, T. (2018). Breast Cancer Immunotherapy: An Update. *Breast Cancer: Basic and Clinical Research*, 12, 1178223418774802. <https://doi.org/10.1177/1178223418774802>
- Manjunath, M., & Choudhary, B. (2021). Triple-negative breast cancer: A run-through of features, classification and current therapies (Review). *Oncology Letters*, 22(1), 512. <https://doi.org/10.3892/ol.2021.12773>
- Mens, M. M. J., & Ghanbari, M. (2018). Cell Cycle Regulation of Stem Cells by MicroRNAs. *Stem Cell Reviews and Reports*, 14(3), 309–322. <https://doi.org/10.1007/s12015-018-9808-y>
- Nagarajan, D., & McArdle, S. (2018). Immune Landscape of Breast Cancers. *Biomedicines*, 6(1), 20. <https://doi.org/10.3390/biomedicines6010020>
- Nair, A., & Manohar, S. M. (2021). A Flow Cytometric Journey Into Cell Cycle Analysis. *Bioanalysis*, 13(21), 1627–1644. <https://doi.org/10.4155/bio-2021-0071>

- Nguyen, Y. T. K., Moon, J. Y., Ryu, J. Y., Eum, S., Bach, T. T., & Cho, S. K. (2019). Methanol Extract of Aerial Parts of *Pavetta indica* L. Enhances the cytotoxic effect of doxorubicin and induces radiation sensitization in MDA-MB-231 triple-negative breast cancer cells. *Molecules*, 24(12). <https://doi.org/10.3390/molecules24122273>
- Nurhayati, I. P., Khumaira, A., Ilmawati, G. P. N., Meiyanto, E., & Hermawan, A. (2020). Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells. *Asian Pacific Journal of Cancer Prevention: APJCP*, 21(5), 1259–1267. <https://doi.org/10.31557/APJCP.2020.21.5.1259>
- Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. *Pharmaceutics*, 15(7), 1796. <https://doi.org/10.3390/pharmaceutics15071796>
- Poofery, J., Khaw-on, P., Suthawa, S., Sripanidkulchai, B., Tantraworasin, A., Saeteng, S., Siwachat, S., Lertprasertsuke, N., & Banjerdpongchai, R. (2020). Potential of Thai Herbal Extracts on Lung Cancer Treatment by Inducing Apoptosis and Synergizing Chemotherapy. *Molecules*, 25(1), 231. <https://doi.org/10.3390/molecules25010231>
- Pugazhendhi, A., Edison, T. N. J. I., Velmurugan, B. K., Jacob, J. A., & Karuppusamy, I. (2018). Toxicity of Doxorubicin (Dox) to different experimental organ systems. *Life Sciences*, 200, 26–30. <https://doi.org/10.1016/j.lfs.2018.03.023>
- Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Nayik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 139, 111708. <https://doi.org/10.1016/j.biopha.2021.111708>
- Reinert, T., & Barrios, C. H. (2015). Optimal management of hormone receptor positive metastatic breast cancer in 2016. *Therapeutic Advances in Medical Oncology*, 7(6), 304–320. <https://doi.org/10.1177/1758834015608993>
- Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. *Journal of Cancer Research and Therapeutics*, 10(4), 853. <https://doi.org/10.4103/0973-1482.139267>

- Reynolds, C. P., & Maurer, B. J. (2005). Evaluating response to antineoplastic drug combinations in tissue culture models. *Methods in molecular medicine*, 110, 173–183. <https://doi.org/10.1385/1-59259-869-2:173>
- Schoch, C. L., Ciufu, S., Domrachev, M., Hotton, C. L., Kannan, S., Khovanskaya, R., Leipe, D., Mcveigh, R., O'Neill, K., Robbertse, B., Sharma, S., Soussov, V., Sullivan, J. P., Sun, L., Turner, S., & Karsch-Mizrachi, I. (2020). NCBI Taxonomy: a comprehensive update on curation, resources and tools. *Database: The Journal of Biological Databases and Curation*, 2020. <https://doi.org/10.1093/database/baaa062>
- Sawasdee, N., Jantakee, K., Wathikthinnakon, M., Panwong, S., Pekkoh, J., Duangjan, K., Yenchitsomanus, P., & Panya, A. (2023). Microalga *Chlorella* sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT/mTOR signaling pathway. *Biomedicine & Pharmacotherapy*, 160, 114306. <https://doi.org/10.1016/j.biopha.2023.114306>
- Sánchez-Díez, M., Romero-Jiménez, P., Alegría-Aravena, N., Gavira-O'Neill, C. E., Vicente-García, E., Quiroz-Troncoso, J., González-Martos, R., Ramírez-Castillejo, C., & Pastor, J. M. (2025). Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy. *Pharmaceutics*, 17(2), 247. <https://doi.org/10.3390/pharmaceutics17020247>
- Sebayang, A. N. O. (2021). EFEK KARDIOTOKSIK OBAT KEMOTERAPI DOXORUBICIN. *JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia*, 7(1), 1–5. <https://doi.org/10.53366/jimki.v7i1.387>
- SenGupta, S., Parent, C. A., & Bear, J. E. (2021). The principles of directed cell migration. *Nature Reviews. Molecular Cell Biology*, 22(8), 529–547. <https://doi.org/10.1038/s41580-021-00366-6>
- Septisetyani, E. P., Santoso, A., Wisnuwardhani, P. H., & Prasetyaningrum, P. W. (2020). Cytotoxic effects of chemopreventive agents curcumin, naringin and epigallocatechin-3-gallate in C2C12 myoblast cells. *IOP Conference Series: Earth and Environmental Science*, 439(1), 012062. <https://doi.org/10.1088/1755-1315/439/1/012062>
- Sharma, R., Mondal, A. S., & Trivedi, N. (2023). Anticancer potential of algae-derived metabolites: recent updates and breakthroughs. *Future Journal of Pharmaceutical Sciences*, 9(1), 44. <https://doi.org/10.1186/s43094-023-00492-2>

- Shin, H.-J., Kwon, H.-K., Lee, J.-H., Gui, X., Achek, A., Kim, J.-H., & Choi, S. (2015). Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. *Scientific Reports*, 5(1), 15798. <https://doi.org/10.1038/srep15798>
- Sodergren, M. H., Mangal, N., Wasan, H., Sadanandam, A., Balachandran, V. P., Jiao, L. R., & Habib, N. (2020). Immunological combination treatment holds the key to improving survival in pancreatic cancer. *Journal of Cancer Research and Clinical Oncology*, 146(11), 2897–2911. <https://doi.org/10.1007/s00432-020-03332-5>
- Sriramulu, S., Thoidingjam, S., Speers, C., & Nyati, S. (2024). Present and Future of Immunotherapy for Triple-Negative Breast Cancer. *Cancers*, 16(19), 3250. <https://doi.org/10.3390/cancers16193250>
- Tumbath, S., Lakshmi Priya, T., Jayasree, P. R., & Kumar, P. R. M. (2024). Antioxidant and Antiproliferative Potentials of *Curcuma neilgherrensis* Leaf Extracts, With Emphasis on Phytochemical Profiling and Apoptosis Induction in Colorectal Carcinoma HCT116 Cells by the Chloroform Extract. *Scientifica*, 2024(1). <https://doi.org/10.1155/sci5/3560781>
- Utpal, B. K., Dehbia, Z., Zidan, B. M. R. M., Sweilam, S. H., Singh, L. P., Arunkumar, M. S., Sona, M., Panigrahy, U. P., Keerthana, R., Mandadi, S. R., Rab, S. O., Alshehri, M. A., Koula, D., Suliman, M., Nafady, M. H., & Emran, T. Bin. (2024). Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy. *Medical Oncology*, 42(1), 4. <https://doi.org/10.1007/s12032-024-02551-x>
- Vaupel, P., Schmidberger, H., & Mayer, A. (2019). The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. *International Journal of Radiation Biology*, 95(7), 912–919. <https://doi.org/10.1080/09553002.2019.1589653>
- Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. *Journal of Experimental & Clinical Cancer Research*, 30(1), 87. <https://doi.org/10.1186/1756-9966-30-87>
- Wuerstlein, R., & Harbeck, N. (2017). Neoadjuvant Therapy for HER2-positive Breast Cancer. *Reviews on Recent Clinical Trials*, 12(2), 81–92. <https://doi.org/10.2174/1574887112666170202165049>
- Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer*

Research: BCR, 22(1), 61. <https://doi.org/10.1186/s13058-020-01296-5>

Yuliasih, Gatot., (2017). Proceeding Book Seminar and Workshop 9th *National congress of indonesian society for Allergy and Immunology* .

Yuan, S., & Chen, H. (2019). Mathematical rules for synergistic, additive, and antagonistic effects of multi-drug combinations and their application in research and development of combinatorial drugs and special medical food combinations. *Food Science and Human Wellness*, 8(2), 136–141. <https://doi.org/10.1016/j.fshw.2019.01.003>.

Zanotelli, M. R., Zhang, J., & Reinhart-King, C. A. (2021). Mechanoresponsive metabolism in cancer cell migration and metastasis. *Cell Metabolism*, 33(7), 1307–1321. <https://doi.org/10.1016/j.cmet.2021.04.002>

Zhang, C.-L., Huang, T., Wu, B.-L., He, W.-X., & Liu, D. (2017). Stem cells in cancer therapy: opportunities and challenges. *Oncotarget*, 8(43), 75756–75766. <https://doi.org/10.18632/oncotarget.20798>

Zhang, L., Mu, C., Zhang, T., Yang, D., Wang, C., Chen, Q., Tang, L., Fan, L., Liu, C., Shen, J., & Li, H. (2021). Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA. *Journal of Nanobiotechnology*, 19(1), 13. <https://doi.org/10.1186/s12951-020-00758-4>

